SCHEMBL23552104

SCHEMBL23552104

CCCC(CBr)CC(=O)Cl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.37
ALDH1A1 P00352 2/20 0.34
CHRM1 P11229 1/20 0.34
AKR1A1 P14550 1/20 0.34
CHRM3 P20309 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
ADRA1A P35348 1/20 0.34
HRH1 P35367 1/20 0.34
DRD3 P35462 1/20 0.34
SLC6A3 Q01959 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
TP53 P04637 1/20 0.34
CYP3A4 P08684 2/20 0.33
NFKB1 P19838 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
HDAC7 Q8WUI4 1/20 0.31
HDAC8 Q9BY41 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22245676 1.00 TSHR (0.37) TSHRALDH1A1CHRM1AKR1A1CHRM3
SCHEMBL10609028 0.82 TSHR (0.40) TSHRALDH1A1CHRM1AKR1A1CHRM3
SCHEMBL10609026 0.82 TSHR (0.40) TSHRALDH1A1CHRM1AKR1A1CHRM3
SCHEMBL10609023 0.82 TSHR (0.40) TSHRALDH1A1CHRM1AKR1A1CHRM3
SCHEMBL2415232 0.81
SCHEMBL18263281 0.80 ADRA1A (0.41) TSHRALDH1A1CHRM1AKR1A1CHRM3
SCHEMBL28248434 0.80 TSHR (0.39) TSHRALDH1A1CHRM1AKR1A1CHRM3
SCHEMBL18263279 0.80 ADRA1A (0.41) TSHRALDH1A1CHRM1AKR1A1CHRM3
SCHEMBL18271781 0.80 TSHR (0.39) TSHRALDH1A1CHRM1AKR1A1CHRM3
SCHEMBL27805132 0.80 ADRA1A (0.41) TSHRALDH1A1CHRM1AKR1A1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12365649-B2 Process for the preparation of brivaracetam ALIVUS LIFE SCIENCES LIMITED (IN) 2025-07-22 US disclosed
US-20240010618-A1 PROCESS FOR THE PREPARATION OF BRIVARACETAM ALIVUS LIFE SCIENCES LIMITED (IN) 2024-01-11 US disclosed
CN-106748748-B Preparation method and intermediate of brivaracetam 成都国为生物医药有限公司 2021-08-24 CN disclosed
WO-2021124066-A1 PROCESS FOR THE PREPARATION OF BRIVARACETAM GLENMARK LIFE SCIENCES LIMITED (IN) 2021-06-24 WO disclosed
CN-106748748-A A kind of Preparation Method And Their Intermediate of Bu Waxitan 成都国弘医药有限公司 2017-05-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12365649-B2 Process for the preparation of brivaracetam CYP2C19, CYP2B6, POR TSHR 865/4885ALDH1A1 1369/4885CHRM1 224/4885
US-20240010618-A1 PROCESS FOR THE PREPARATION OF BRIVARACETAM CYP2C19, CYP2B6, POR TSHR 865/4885ALDH1A1 1369/4885CHRM1 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.